Feed AXGN
AX

AxoGen, Inc.

AXGN · NASDAQ

$45.93 +1.83% (+$0.83)
1M -6.70%
Market Cap $2.47B
P/E Ratio -
Div. Yield -
ROE 17.88%

Bulios Fair Price

$24.96

45.7% downside

Current Price

$45.93

Undervalued Fair Value Overvalued

According to Bulios Fair Price, AXGN is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
0 /100
Expensive
P/S 9.83x
P/FCF 977.54x
P/B 9.64x
Growth
92 /100
Growing
Rev. growth 17.57%
Book val. growth 8.46%
EPS growth N/A
Profitability
24 /100
Weak
Gross margin 74.56%
FCF margin 1.01%
Net margin 13.36%
Quality
10 /100
Poor
ROIC 4.65%
Asset turnover 0.82x
ROE 17.88%
Debt
69 /100
Low
Debt/Equity 0.08x
Int. coverage -1.71x
Current ratio 6.60x
Stability
58 /100
Moderate
Beta 1.16x
Profitable years 0
Rev. volatility 2.74%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about AXGN
Online

About the company

AxoGen, Inc. (AXGN) is a biotechnology company focused on the development and manufacture of innovative therapeutic products and therapies for peripheral nerve repair. Their products are designed to aid patients with peripheral nerve damage caused by traumatic injuries or surgical procedures. AxoGen specializes in utilizing advanced technologies and biological materials to support nerve cell regeneration and restore nervous system function. The company is a leading player in the field of regenerative medicine and is focused on providing innovative solutions for the treatment of patients with nerve injuries. Shares of AxoGen, Inc. (AXGN) may be attractive to investors seeking opportunities in the biotechnology and regenerative medicine sector.

Sector

Healthcare

Industry

Medical - Devices

CEO

Michael D. Dale

Employees

622

Headquarters

Alachua

Upcoming events

04 NOV

Earnings

Upcoming earnings report

43d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.